undamentalytics Newsletter
Sign in

Myriad Genetics Inc balance sheet

At the end of fiscal 2025, Myriad Genetics Inc had total assets of $707m, total liabilities of $339m and shareholders' equity of $368m. It held $150m in cash against $125m of debt: net cash of $24.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Jun 20092010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents————————————25757132102150115
Receivables—48506094828692891001346891102114121115110
Inventory——812524253842343129152022283131
Total current assets—474418422484322284315302328349332485275314298333289
Goodwill——5657571691771953163194173282392872872865247
Total assets—5946116918048247668811,2091,1751,5631,4051,3211,1991,1471,028707639
Accounts payable—911101823212122263322302926323030
Deferred revenue (current)——12212233233511———
Total current liabilities—27344565816972218102118147204137156164134131
Short-term debt———————————————0——
Long-term debt————————999234224003940120121
Total debt0000000010010235227003941125125
Total liabilities—36445575105104132441209474486353313363327339335
Shareholders' equity4345585676367297196627407689661,089918968886783701368304
Net debt (negative = net cash)————————————−257−57−94−62−2510
Shares outstanding—94m86m83m81m74m69m69m68m71m74m75m80m81m90m91m94m96m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IRTC vs MYGNMYGN vs OFIXATEC vs MYGN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Myriad Genetics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Myriad Genetics Inc.